Overview

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
To see how well enzastaurin in combination with irinotecan and cetuximab works versus irinotecan and cetuximab in participants who have progressed within 3 months.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Camptothecin
Cetuximab
Irinotecan